1. Home
  2. ONCY vs TNXP Comparison

ONCY vs TNXP Comparison

Compare ONCY & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oncolytics Biotech Inc.

ONCY

Oncolytics Biotech Inc.

N/A

Current Price

$0.38

Market Cap

80.5M

Sector

Health Care

ML Signal

N/A

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$2.95

Market Cap

81.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ONCY
TNXP
Founded
1998
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.5M
81.3M
IPO Year
2002
2008

Fundamental Metrics

Financial Performance
Metric
ONCY
TNXP
Price
$0.38
$2.95
Analyst Decision
Buy
Strong Buy
Analyst Count
5
4
Target Price
$4.42
★ $34.00
AVG Volume (30 Days)
953.1K
★ 1.0M
Earning Date
11-24-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 91.75
EPS
★ N/A
N/A
Revenue
N/A
★ $13,107,000.00
Revenue This Year
N/A
$333.23
Revenue Next Year
N/A
$99.37
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 29.85
52 Week Low
$0.37
$3.21
52 Week High
$1.30
$20.56

Technical Indicators

Market Signals
Indicator
ONCY
TNXP
Relative Strength Index (RSI) 32.34 11.64
Support Level N/A N/A
Resistance Level $0.46 $12.99
Average True Range (ATR) 0.04 0.41
MACD 0.00 -0.03
Stochastic Oscillator 25.50 2.49

Price Performance

Historical Comparison
ONCY
TNXP

About ONCY Oncolytics Biotech Inc.

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: